CL2024000776A1 - Milvexian para la prevención y el tratamiento de trastornos tromboembólicos - Google Patents
Milvexian para la prevención y el tratamiento de trastornos tromboembólicosInfo
- Publication number
- CL2024000776A1 CL2024000776A1 CL2024000776A CL2024000776A CL2024000776A1 CL 2024000776 A1 CL2024000776 A1 CL 2024000776A1 CL 2024000776 A CL2024000776 A CL 2024000776A CL 2024000776 A CL2024000776 A CL 2024000776A CL 2024000776 A1 CL2024000776 A1 CL 2024000776A1
- Authority
- CL
- Chile
- Prior art keywords
- milvexian
- prevention
- treatment
- thromboembolic disorders
- disorders
- Prior art date
Links
- 230000009424 thromboembolic effect Effects 0.000 title abstract 2
- FSWFYCYPTDLKON-CMJOXMDJSA-N (9R,13S)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxopyrimidin-1-yl]-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one Chemical compound C[C@@H]1CCC[C@H](N2C=NC(=CC2=O)C2=C(C=CC(Cl)=C2)N2C=C(Cl)N=N2)C2=NC=CC(=C2)C2=C(NC1=O)C=NN2C(F)F FSWFYCYPTDLKON-CMJOXMDJSA-N 0.000 title 1
- 229940073199 milvexian Drugs 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229940122036 Factor XIa inhibitor Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245522P | 2021-09-17 | 2021-09-17 | |
| US202163278582P | 2021-11-12 | 2021-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000776A1 true CL2024000776A1 (es) | 2024-07-26 |
Family
ID=83688923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000776A CL2024000776A1 (es) | 2021-09-17 | 2024-03-15 | Milvexian para la prevención y el tratamiento de trastornos tromboembólicos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250099466A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4401736A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024534427A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240060820A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022345862A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232633A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024000776A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310894A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024002857A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202327607A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023043999A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4565231A1 (en) * | 2022-08-01 | 2025-06-11 | Bristol-Myers Squibb Company | Use of milvexian for treating or preventing ischemic stroke |
| CN121001727A (zh) * | 2023-04-19 | 2025-11-21 | 百时美施贵宝公司 | 米尔维仙(milvexian)于治疗及预防患有心血管或脑血管疾病的患者的血栓病况的用途 |
| CN121443289A (zh) * | 2023-04-19 | 2026-01-30 | 百时美施贵宝公司 | 米尔维仙在治疗或预防患有急性冠状动脉综合征的患者的不良脑血管事件或不良心血管事件中的用途 |
| CN121398811A (zh) * | 2023-04-19 | 2026-01-23 | 百时美施贵宝公司 | 米尔维仙于治疗及预防患有心房颤动的患者的血栓病况的用途 |
| WO2025126240A1 (en) * | 2023-12-12 | 2025-06-19 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions and use thereof |
| WO2026115567A1 (en) * | 2024-11-26 | 2026-06-04 | Dr. Reddy’S Laboratories Limited | Sustained release formulations of milvexian |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453018B2 (en) * | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| KR20210151183A (ko) | 2019-04-11 | 2021-12-13 | 브리스톨-마이어스 스큅 컴퍼니 | 치료 혈장 농도를 달성하기 위한 무정형 고체 및 가용화된 제제의 증진된 성능 |
-
2022
- 2022-09-16 JP JP2024516849A patent/JP2024534427A/ja active Pending
- 2022-09-16 IL IL310894A patent/IL310894A/en unknown
- 2022-09-16 KR KR1020247012366A patent/KR20240060820A/ko active Pending
- 2022-09-16 MX MX2024002857A patent/MX2024002857A/es unknown
- 2022-09-16 AU AU2022345862A patent/AU2022345862A1/en active Pending
- 2022-09-16 TW TW111135090A patent/TW202327607A/zh unknown
- 2022-09-16 CA CA3232633A patent/CA3232633A1/en active Pending
- 2022-09-16 WO PCT/US2022/043797 patent/WO2023043999A1/en not_active Ceased
- 2022-09-16 EP EP22786640.7A patent/EP4401736A1/en active Pending
- 2022-09-16 US US18/692,560 patent/US20250099466A1/en active Pending
-
2024
- 2024-03-15 CL CL2024000776A patent/CL2024000776A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250099466A1 (en) | 2025-03-27 |
| JP2024534427A (ja) | 2024-09-20 |
| KR20240060820A (ko) | 2024-05-08 |
| TW202327607A (zh) | 2023-07-16 |
| CA3232633A1 (en) | 2023-03-23 |
| AU2022345862A1 (en) | 2024-03-14 |
| MX2024002857A (es) | 2024-03-21 |
| IL310894A (en) | 2024-04-01 |
| WO2023043999A1 (en) | 2023-03-23 |
| EP4401736A1 (en) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024002857A (es) | Milvexian para la prevencion y el tratamiento de trastornos tromboembolicos. | |
| JOP20220263A1 (ar) | مثبط ret بلوري | |
| CL2022003348A1 (es) | Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios | |
| CL2023003068A1 (es) | Compuestos, composiciones y métodos para el tratamiento de trastornos | |
| MX2025004367A (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| CY1122867T1 (el) | Συνθεσεις που περιλαμβανουν ενα βακτηριακο στελεχος του blautia hydrogenotrophica για χρηση στην θεραπεια ή προληψη διαρροιας ή δυσκοιλιοτητας | |
| UY37554A (es) | (aza)indol- y benzofuran-3-sulfonamidas | |
| AR115583A1 (es) | Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado | |
| PH12021551455A1 (en) | Jak1 pathway inhibitors for the treatment of gastrointestinal disease | |
| MX2019003703A (es) | Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23. | |
| MX2020009942A (es) | Compuestos y usos de los mismos. | |
| CO2024009571A2 (es) | Inhibidores de parp1 | |
| MX2019008124A (es) | Metodos para el tratamiento de trastornos neurologicos. | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| CO2018013020A2 (es) | Combinaciones farmacéuticas para el tratamiento del cáncer | |
| CL2020001888A1 (es) | Terapia de combinación para tratar o prevenir el cáncer. | |
| MX2020008456A (es) | Uso de tradipitant para tratar la cinetosis. | |
| PH12019502315A1 (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
| MX2019010060A (es) | Composiciones y metodo para tratar cancer. | |
| MX2023002851A (es) | Tratamiento de la enfermedad de parkinson. | |
| EP4556072A3 (en) | Compositions for monocyte and macrophage polarization and methods of use | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. |